Literature DB >> 14971281

The role of intraoperative quick PTH measurements in primary hyperparathyroidism.

G Prager1, P Riss, C Bieglmayer, B Niederle.   

Abstract

BACKGROUND: In patients with primary hyperparathyroidism (PHPT), circulating concentrations of intact parathyroid hormone (PTH), decline dramatically within minutes following surgical excision of hyperfunctioning parathyroid tissue. The magnitude of this decay correlates with the completeness of resection of hyperfunctioning parathyroid tissue and can be monitored during the operation.
METHOD: Intraoperative Quick PTH (QPTH) monitoring and pitfalls of more than 350 patients, who were operated because of primary hyperparathyroidism are analyzed. Special attention is given to correct baseline values and interpretation of QPTH values.
RESULTS: QPTH monitoring is able to distinguish reliably between single and multiple gland disease and is an indispensable prerequisite for any form of limited parathyroid exploration. Experience with QPTH monitoring is necessary to achieve the excellent results known from bilateral neck exploration.
CONCLUSION: Applying correct baseline values and cautious interpretation of QPTH values results in excellent results. Nevertheless more data must be collected to allow reliable interpretation of QPTH monitoring in all patients with PHPT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14971281

Source DB:  PubMed          Journal:  Ann Ital Chir        ISSN: 0003-469X            Impact factor:   0.766


  2 in total

1.  PTH spikes during parathyroid exploration--a possible pitfall during PTH monitoring?

Authors:  Philipp Riss; Klaus Kaczirek; Christian Bieglmayer; Bruno Niederle
Journal:  Langenbecks Arch Surg       Date:  2006-12-23       Impact factor: 3.445

2.  Intra-operative quick insulin assay to confirm complete resection of insulinomas guided by selective arterial calcium injection (SACI).

Authors:  Oliver Gimm; Evelyn König; Phuong Nguyen Thanh; Michael Brauckhoff; Wolfram Karges; Henning Dralle
Journal:  Langenbecks Arch Surg       Date:  2007-02-09       Impact factor: 3.445

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.